Endometrioid Adenocarcinoma — Trials

Endometrioid Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 55
Recruiting: 24
Ph III recruiting: 6
Growth YoY: —
Industry share: 5%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (17)

clinicaltrialsPublishedShowing 51–59 of 59 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00993616	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin	completed	Phase 2	29	National Cancer Institute (NCI)NIH	1	Jul 23, 2019	clinicaltrials
NCT01010126	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	completed	Phase 2	252	National Cancer Institute (NCI)NIH	2